Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Alemtuzumab
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
A full genome search in multiple sclerosis.
UCSF Seminar: "Dynamics of Retina Damage in Acute Optic Neuritis"
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Drug Safety Labeling Changes

Pages